Provides the pharmacy element of the CMDU pathway, offering clinical review, interaction and renal dosing checks, patient counselling and the safe and urgent supply of oral COVID 19 treatments for eligible high risk patients.

Description of the services to be provided: Provides the pharmacy element of the CMDU pathway, offering clinical review, interaction and renal dosing checks, patient counselling and the safe and urgent supply of oral COVID 19 treatments for eligible high risk patients. The ICB is intending to award a contract to an existing provider following direct award process C. The contract is paid on activity The dates between which the services are intended to be provided are 1 April 2026 to 30 September 2027